OTCMKTS:DNPUF

Sumitomo Dainippon Pharma Competitors

$17.40
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.40
Now: $17.40
$17.40
50-Day Range
$16.50
MA: $17.53
$18.75
52-Week Range
$12.45
Now: $17.40
$18.75
VolumeN/A
Average Volume978 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying DNPUF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Sumitomo Dainippon Pharma, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Abacus Health Products (OTCMKTS:ABAHF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Abacus Health Products and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abacus Health Products0000N/A
Sumitomo Dainippon Pharma0000N/A

Profitability

This table compares Abacus Health Products and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abacus Health ProductsN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Earnings & Valuation

This table compares Abacus Health Products and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abacus Health ProductsN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Acreage (OTCMKTS:ACRGF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Acreage and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
Sumitomo Dainippon Pharma0000N/A

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, research analysts plainly believe Acreage is more favorable than Sumitomo Dainippon Pharma.

Profitability

This table compares Acreage and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Earnings & Valuation

This table compares Acreage and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Summary

Acreage beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Applied Biosciences and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
Sumitomo Dainippon Pharma0000N/A

Profitability

This table compares Applied Biosciences and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Earnings & Valuation

This table compares Applied Biosciences and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Ayr Strategies (OTCMKTS:AYRSF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Ayr Strategies and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Earnings & Valuation

This table compares Ayr Strategies and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Ayr Strategies and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Sumitomo Dainippon Pharma0000N/A

Ayr Strategies currently has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, research analysts plainly believe Ayr Strategies is more favorable than Sumitomo Dainippon Pharma.

Summary

Ayr Strategies beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Can B and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Valuation & Earnings

This table compares Can B and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Can B and Sumitomo Dainippon Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Sumitomo Dainippon Pharma0000N/A

Cansortium (OTCMKTS:CNTMF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Cansortium and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CansortiumN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/A

Valuation & Earnings

This table compares Cansortium and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CansortiumN/AN/AN/AN/AN/A
Sumitomo Dainippon PharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Cansortium and Sumitomo Dainippon Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cansortium00103.00
Sumitomo Dainippon Pharma0000N/A

Cansortium currently has a consensus price target of $1.20, indicating a potential upside of 18.81%. Given Cansortium's higher possible upside, equities analysts clearly believe Cansortium is more favorable than Sumitomo Dainippon Pharma.

Summary

Cansortium beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.


Sumitomo Dainippon Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.22flat$0.00N/A0.00Increase in Short Interest
Gap Up
AYRSF
Ayr Strategies
1.4$21.26flat$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.49flat$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.01flat$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.06flat$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.10flat$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.09flat$0.00N/A0.00Decrease in Short Interest
Gap Down
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22flat$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.40flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.17flat$0.00N/A0.00Gap Up
Curaleaf logo
CURLF
Curaleaf
1.6$13.84flat$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00flat$0.00N/A0.00Decrease in Short Interest
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.14flat$0.00N/A0.00Gap Up
EVIO logo
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00News Coverage
Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.22flat$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00News Coverage
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.31flat$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62flat$0.00N/A0.00Increase in Short Interest
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.82flat$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68flat$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22flat$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.32flat$0.00N/A0.00Decrease in Short Interest
News Coverage
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.07flat$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.40flat$0.00N/A0.00Decrease in Short Interest
KHTRF
Knight Therapeutics
1.2$4.22flat$0.00N/A0.00High Trading Volume
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
News Coverage
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04flat$0.00N/A0.00Gap Up
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.38flat$0.00N/A0.00Analyst Report
Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.30flat$0.00N/A0.00Increase in Short Interest
Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.76flat$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07flat$0.00N/A0.00Gap Down
MYHI
Mountain High Acquisitions
0.5$0.02flat$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.25flat$0.00N/A0.00
Plus Products logo
PLPRF
Plus Products
1.1$0.52flat$0.00N/A0.00Decrease in Short Interest
Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00
PCYN
Procyon
0.4$0.60flat$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Decrease in Short Interest
News Coverage
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00News Coverage
Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.39flat$0.00N/A0.00Increase in Short Interest
Gap Down
TerrAscend logo
TRSSF
TerrAscend
1.7$10.02flat$0.00N/A0.00Analyst Report
Increase in Short Interest
Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.25flat$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.30flat$0.00N/A0.00Analyst Report
News Coverage
Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.